Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDIV 1

Study Type

Interventional 22Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 30Drug Therapy 27Immunotherapy 25Surgical Procedures, Operative 22Carboplatin 22Nivolumab 21Immune Checkpoint Inhibitors 20pembrolizumab 18osimertinib 18atezolizumab 17Observation 17Radiotherapy 16Bevacizumab 15Cisplatin 14Afatinib 14Specimen Handling 13Gene Expression Profiling 13Erlotinib Hydrochloride 13lorlatinib 12Pemetrexed 12Magnetic Resonance Spectroscopy 11Ipilimumab 11Immunohistochemistry 11Biopsy 11durvalumab 10alectinib 10Paclitaxel 10Bronchoscopy 10Tomography, X-Ray Computed 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × sargramostim × Thoracic × Clear all
NCT03695835 2020-07-22

NIRPA

Gary Onik MD

Completed
27 enrolled
GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡